Grufity logoGrufity logo

ABMD

377.44USD-0.35(-0.09%)Market Closed

Abiomed Inc

Market Summary

USD377.44-0.35Market Closed
-0.09%

ABMD Stock Price

RSI Chart

Valuation

Market Cap

11.7B

Price/Earnings

53.92

Price/Sales

11.11

Price/Cashflow

39.35

MarketCap/EBT

43.49

Price/Sales

Profitability

EBT Margin

25.54%

Return on Equity

14.16%

Return on Assets

12.77%

Fundamentals

Revenue

Revenue (TTM)

1.1B

Revenue Y/Y

9.73%

Revenue Q/Q

2.7%

Earnings

Earnings (TTM)

217.6M

Earnings Y/Y

305.67%

Earnings Q/Q

-9.57%

Price Action

52 Week Range

219.85381.99
(Low)(High)

Last 7 days

-0.1%

Last 30 days

-0.1%

Last 90 days

44.5%

Trailing 12 Months

23.5%

Financial Health

Current Ratio

7.53

Investor Care

Shares Dilution (1Y)

0.18%

Diluted EPS (TTM)

4.75

Peers (Alternatives to Abiomed)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-13.56% 48.60%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
9.40% 1.57%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
11.19% -14.20%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
7.25% 7.47%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
7.86% 20.92%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
6.85% -27.80%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
12.82% 19.67%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
29.82% -13.72%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-14.51% 1.73%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-23.89% -65.81%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
20.67% 27.67%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
5.19% 0.37%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
20.86% -8.66%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-3.52% -27.68%
-16.43
2.57
-8.79% -175.19%

Financials for Abiomed

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue2.4%1,0561,0321,003974935
  S&GA Expenses3.4%438423414393369
  R&D Expenses1.7%166163152144133
Earnings Before Taxes41.5%270191189212218
Net Income59.4%218137133149154
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets1.8%1,7041,6731,5931,5301,458
  Current Assets8.6%1,060976885871730
    Cash Equivalents35.9%180133144242175
  Inventory1.5%9594908684
  Net PPE-2.0%198202197197198
  Goodwill-2.5%7577777879
Liabilities-1.5%167170160145151
  Current Liabilities1.7%141138127114113
Shareholder's Equity2.2%1,5361,5031,4331,3851,308
  Retained Earnings5.7%1,019965904858801
  Additional Paid-In Capital1.7%885870853840815
Accumulated Depreciation3.9%106102999388
Shares Outstanding0.0%4646464545
Float-14,400----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations4.5%298285293282298
  Share Based Compensation1.4%5353545550
Cashflow From Investing30.8%-263.82-380.99-324.66-250.42-346.15
Cashflow From Financing-747.8%-18.67-2.20-1.5865
  Buy BacksInfinity%580
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on ABMD?

78.8%


Probability that Abiomed stock will be more than 20% underwater in next one year

56.9%


Probability that Abiomed stock will be more than 30% underwater in next one year.

31.5%


Probability that Abiomed stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ABMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Abiomed was unfortunately bought at previous high price.

Returns

Cumulative Returns on ABMD

40.3%


10-Year Cumulative Returns

25.0%


7-Year Cumulative Returns

14.2%


5-Year Cumulative Returns

25.2%


3-Year Cumulative Returns

What are the long-term rolling returns for ABMD?

FIve years rolling returns for Abiomed.

Which funds bought or sold ABMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
ADDED
244.35
139,073
196,000
0.12%
2022-11-23
Toroso Investments, LLC
ADDED
3.11
16,000
684,000
0.03%
2022-11-22
CVA Family Office, LLC
UNCHANGED
-
-
22,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
9,667,000
9,667,000
0.11%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
3.53
6,000
217,000
0.01%
2022-11-21
FourThought Financial, LLC
REDUCED
-6.88
-6,000
73,000
0.01%
2022-11-21
17 CAPITAL PARTNERS, LLC
UNCHANGED
-
-2,000
281,000
0.38%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.01
-325,000
18,306,000
0.03%
2022-11-18
National Pension Service
ADDED
552,264
19,249,000
19,252,000
0.04%
2022-11-17
M&T Bank Corp
REDUCED
-4.06
-4,000
475,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying ABMD calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ABMD

Abiomed News

The Motley Fool

3 Healthcare Stocks to Buy and Hold for the Next 10 Years.2 hours ago

Investor's Business Daily

GuruFocus.com

ABMD Fair Value

Recent SEC filings of Abiomed

View All Filings
Date Filed Form Type Document
Nov 17, 2022
4
Insider Trading
Nov 15, 2022
SC 14D9
SC 14D9
Nov 15, 2022
SC TO-T
SC TO-T
Nov 14, 2022
SC14D9C
SC14D9C
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 07, 2022
SC14D9C
SC14D9C
Nov 07, 2022
SC TO-C
SC TO-C

Latest Insider Trading transactions for ABMD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-02-17
Rolle Myron L
SOLD (Taxes)
-36,447
325.42
-112
-
2022-02-17
SUTTER MARTIN P
SOLD
-1,258,850
314.713
-4,000
-
2022-02-16
SUTTER MARTIN P
SOLD
-617,322
308.661
-2,000
-
2022-02-16
Weber David M
SOLD
-2,437,500
325
-7,500
Chief Operating Officer
2022-02-15
SUTTER MARTIN P
SOLD
-607,301
303.65
-2,000
-
2022-02-09
Weber David M
SOLD
-965,311
310.19
-3,112
Chief Operating Officer
2022-02-09
Weber David M
ACQUIRED
67,063.6
21.55
3,112
Chief Operating Officer
2022-02-08
Weber David M
ACQUIRED
159,750
21.55
7,413
Chief Operating Officer
2022-02-08
Weber David M
SOLD
-2,245,420
302.903
-7,413
Chief Operating Officer
2022-02-07
Weber David M
ACQUIRED
6,465
21.55
300
Chief Operating Officer

1–10 of 50

Michael R. Minogue
2000
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

ABMD Income Statement

2022-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 265,921$ 248,142$ 543,070$ 500,727
Costs and expenses:    
Cost of revenue48,88043,886101,50689,074
Research and development42,08941,04182,56678,749
Selling, general and administrative116,958102,779234,954206,263
Acquired in-process research and development000115,490
Costs and Expenses, Total207,927187,706419,026489,576
Other (loss) income:    
Income from operations57,99460,436124,04411,151
Interest and other income, net80,7096,83584,48146,770
Income before income taxes138,70367,271208,52557,921
Income tax provision32,57010,31847,83827,493
Net income$ 106,133$ 56,953$ 160,687$ 30,428
Net income per share - basic$ 2.34$ 1.25$ 3.53$ 0.67
Weighted average shares outstanding - basic45,37245,43745,47545,374
Net income per share - diluted$ 2.32$ 1.24$ 3.51$ 0.66
Weighted average shares outstanding - diluted45,71145,89345,81245,857

ABMD Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Mar. 31, 2022
Current assets:  
Cash and cash equivalents$ 182,335$ 132,818
Short-term marketable securities638,037625,789
Accounts receivable, net94,47590,608
Inventories, net102,23793,981
Prepaid expenses and other current assets45,71433,277
Total current assets1,062,798976,473
Long-term marketable securities116,871220,089
Property and equipment, net195,157202,490
Goodwill72,96076,786
Other intangibles, net36,83339,518
Deferred tax assets18,88110,552
Other assets193,044147,485
Total assets1,696,5441,673,393
Current liabilities:  
Accounts payable35,07035,346
Accrued expenses69,43472,629
Deferred revenue25,96226,362
Other current liabilities3,5944,120
Total current liabilities134,060138,457
Other long-term liabilities7,0139,319
Contingent consideration14,99521,510
Deferred tax liabilities689781
Total liabilities156,757170,067
Commitments and contingencies (Note 16)
Stockholders' equity:  
Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none
Common stock, $.01 par value 100,000 shares authorized; 48,418 and 48,258 shares issued as of September 31, 2022 and March 31, 2022, respectively 45,172 and 45,545 shares outstanding as of September 30, 2022 and March 31, 2022, respectively452455
Additional paid in capital904,755870,074
Retained earnings1,125,199964,512
Treasury stock at cost - 3,246 and 2,713 shares as of September 31, 2022 and March 31, 2022, respectively(443,974)(304,555)
Accumulated other comprehensive loss(46,645)(27,160)
Total stockholders' equity1,539,7871,503,326
Total liabilities and stockholders' equity$ 1,696,544$ 1,673,393